02 May 2021>: Clinical Research
Parameters Indicating Development of Influenza-Associated Acute Necrotizing Encephalopathy: Experiences from a Single Center
Suyun Li 1AE* , Dandan Hu 2AE* , Peiqing Li 1AE* , Weiqiang Xiao 3AE* , Huixian Li 4ACE* , Guangming Liu 1C , Yongling Song 1C , Shuyao Ning 2C , Qiuyan Peng 1F , Danyang Zhao 5F , Minxiong Situ 5F , Wanqi Li 1B , Peiqun Wu 1B , Jipeng Zheng 1B , Yueting Liu 1B , Lin Hu 1B , Pengfei Wang 1B , Zhengbin Hu 1B , Wencheng Ma 1D , Jun Shen 1D , Sida Yang 2A*DOI: 10.12659/MSM.930688
Med Sci Monit 2021; 27:e930688
Table 2 Biochemical test.
Characteristics, mean (SD) or median (SQR) | FA, n=4 | FS, n=8 | IAE, n=14 | IANE, n=5 |
---|---|---|---|---|
Routine blood | ||||
WCB (10/L) | 6.5 (2.3) | 9.8 (4.3) | 7.7 (3.9) | 7.5 (3.4) |
N (10/L) | 4.7 (2.2) | 7.5 (4) | 5.2 (3) | 4.6 (2.9) |
L (10/L) | 1.1 (0.7, 2) | 1.7 (1, 2) | 1.2 (0.7, 2.1) | 1.8 (1.6, 2.1) |
M (10/L) | 0.5 (0.4, 0.6) | 0.8 (0.4, 1) | 0.7 (0.5, 0.9) | 0.6 (0.3, 0.9) |
Hb (g/L) | 119.5 (113, 120.5) | 118 (115, 121.5) | 124.5 (114, 125) | 110 (100, 115) |
Plt (10/L) | 302.5 (187.5, 402) | 235 (213.5, 269.5) | 223.5 (200, 280) | 232 (225, 271) |
CSF | ||||
WBC (10/L) | – | 4 (3, 5) | 2 (1, 2.5) | 1 (1, 2) |
HsCRP (mg/L) | – | 0.3 (0, 0.3) | 0.2 (0, 0.3) | 0.2 (0.1, 0.3) |
CL (mmol/L) | – | 118.2 (118, 126.9) | 122.4 (120, 123.2) | 123.8 (122, 125.4) |
GLU (mmol/L) | – | 3.5 (3.2, 3.5) | 3.8 (3.4, 4.2) | 3.8 (3.4, 4.1) |
MP (g/L) | – | 0.3 (0.1, 0.3) | 0.2 (0.2, 0.3) | 0.6 (0.2, 0.7) |
LDH (U/L) | – | 17 (14, 18) | 15 (15, 17) | 20 (15, 32) |
Electrolyte | ||||
Na (mmol/L) | 134.2 (6.4) | 132.5 (4.3) | 132.1 (4.1) | 132.9 (3.2) |
K (mmol/L) | 3.2 (0.7) | 4 (0.7) | 3.6 (0.5) | 4 (0.4) |
BG (mmol/L) | 9.2 (6.6, 10.8) | 5.6 (5.4, 5.9) | 5.1 (4.8, 5.9) | 6.4 (6.3, 8.3) |
Lac (mmol/L) | 1.3 (1.2, 1.5) | 1.7 (1.3, 2.1) | 1 (0.8, 1.5) | 1.5 (1.4, 2.9) |
Organ biochemical | ||||
ALT (U/L) | 21 (18.5, 42) | 14 (12.5, 22) | 16.5 (13, 22) | 89 (59, 122),** |
AST (U/L) | 74 (41.5, 143.5) | 36 (31, 43.5) | 40 (30, 46) | 147 (94, 205),** |
ALT/AST | 0.4 (0.3, 0.5) | 0.4 (0.4, 0.5) | 0.4 (0.3, 0.6) | 0.3 (0.3, 1) |
LDH (U/L) | 415 (383, 508) | 248 (239.5, 257)* | 269 (214, 290)* | 490 (366, 606),** |
CK (U/L) | 1632 (253.5, 5235) | 165 (147.5, 235.5) | 144 (110, 269) | 305 (131, 1340) |
CK_MB (U/L) | 51 (19, 96) | 23 (17, 30) | 25 (15, 36) | 50 (40, 58) |
Ammonia (umol/L) | 58.8 (45.6) | 23.2 (12.4) | 29 (8.8) | 24.3 (3.7) |
Immune indexes | ||||
IgG (g/L) | 11.3 (5.3) | 10.4 (1.5) | 9.7 (2.3) | 12.3 (5.7) |
IgA (g/L) | 1.8 (1) | 0.9 (0.3) | 1.1 (0.6) | 1 (0.8) |
IgM (g/L) | 1.1 (0.3) | 1.6 (0.9) | 1.2 (0.3) | 1.4 (0.5) |
C3 (g/L) | 0.9 (0.1) | 0.8 (0.1) | 0.9 (0.2) | 0.8 (0.2) |
C4 (g/L) | 0.2 (0.1) | 0.3 (0.1) | 0.2 (0.1) | 0.3 (0.1) |
IgE (IU/ML) | 77 (42.5, 94.5) | 60 (31.5, 120) | 72.5 (26, 185) | 10 (7, 15) |
Blood coagulation | ||||
PT (s) | 12.9 (12.5, 13.2) | 15.1 (14.5, 15.6) | 14.5 (13.5, 15) | 15.4 (15.2, 16) |
APTT(s) | 41 (15.3) | 46.5 (6) | 43.4 (5.6) | 44 (9.7) |
INR | 1 (0) | 1.2 (0.1) | 1.1 (0.1) | 1.2 (0.2) |
FIB (g/L) | 3.8 (3.4, 4) | 2.6 (2.5, 3.3) | 2.7 (2.4, 3) | 2.5 (2.1, 2.6) |
* FA group were selected as controls and p-value ** FS group were selected as controls and p-value *** IAE group were selected as controls and -value |